(Q43864993)

27 November 2017

title

Insulin-metformin combination therapy in obese patients with type 2 diabetes (English)

1 reference

27 November 2017

0 references

1 reference

1 reference

Linda A Jaber

1

1 reference

27 November 2017

Sandra N Nowak

series ordinal

2

1 reference

27 November 2017

Richard R Slaughter

series ordinal

3

1 reference

27 November 2017

publication date

1 January 2002

1 reference

The Journal of Clinical Pharmacology

27 November 2017

published in

1 reference

27 November 2017

volume

42

1 reference

27 November 2017

issue

1

1 reference

27 November 2017

page(s)

89-94

1 reference

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

Insulin therapy in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

Metformin added to insulin therapy in poorly controlled type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002042001010

10.1177/0091270002042001010

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference